An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer

Published:2020-03-03 Issue:8 Volume:21 Page:863-870
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Nauseef Jones T.¹,Villamar Dario M.²,Lebenthal Justin²,Vlachostergios Panagiotis J.¹,Tagawa Scott T.¹³⁴

Affiliation:

1. Department of Medicine, Division of Hematology & Oncology, Weill Cornell Medicine, New York, NY, USA

2. Department of Medicine, Division of Internal Medicine, New York Presbyterian Hospital - Weill Cornell Medicine, New York, NY, USA

3. Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA

4. Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2020.1736036

Reference47 articles.

1. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

2. Cancer statistics, 2019

3. Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary

4. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

5. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and characterizations of some new selenolo[2,3‐b]quinoxaline derivatives;Journal of Heterocyclic Chemistry;2023-11-15

2. Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+);Cancers;2022-10-27

3. Ecofriendly, Simple, Fast and Sensitive UPLC-MS/MS Method for Determination of Erdafitinib, a Novel Tyrosine Kinase Inhibitor, in Plasma and Its Application to Metabolic Stability;Applied Sciences;2022-08-28

4. Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now;Current Treatment Options in Oncology;2022-08-13

5. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations;Future Oncology;2022-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3